Isofol Medical AB (ISOFOL) AI Stock Analysis

• Market Cap: kr193.96M
• Dividend Yield: N/A
• Average Volume (3M): 501.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: -34.02%
• Country: SE
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 281,107,240
• 10 Day Avg. Volume: 847,726
• 30 Day Avg. Volume: 501,890
• PEG Ratio: 0.39
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.2
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: kr0.76 ▲(5.42% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily constrained by weak financial performance—no recent revenue, ongoing losses, and continued cash burn—despite low leverage and improved burn versus earlier years. Technicals are moderately positive with price above key moving averages and supportive momentum, but valuation remains pressured due to unprofitability and no dividend data.

Positive Factors

Low leverage / no debt

Isofol's near-zero debt reduces interest burden and lowers solvency risk, an important durable advantage for an R&D-heavy biotech. With no scheduled debt service, management can prioritize clinical programs and partnering without near-term refinancing pressure, preserving optionality.

Improved cash burn control

Operating cash outflows have materially narrowed versus earlier years, reflecting tighter cost discipline and more efficient program spend. Sustained lower burn extends runway and reduces frequency/size of future financings, a durable operational improvement for a pre-commercial biotech.

Focused lead asset and partnering model

A clear focus on a single lead candidate (arfolitixorin) and a partnering-centric commercialization strategy concentrates resources on clinical proof points while avoiding the cost of global commercialization. This business model fits stage of development and can scale via partnerships if trials succeed.

Negative Factors

No recent revenue

Revenue at zero in the last two reported years means the company cannot internally fund R&D or absorb fixed costs; revenues will remain a structural constraint until commercialization or milestone/licensing payments occur, keeping reliance on external capital high.

Persistent, growing net losses

Worsening annual net losses signal that operating and development costs still outpace any offsets; sustained negative profitability depletes reserves over time and constrains strategic flexibility, requiring ongoing financing until a commercial or partnership revenue stream is secured.

Equity erosion and funding dependence

Sharp decline in shareholders' equity over several years reflects accumulated losses and/or dilutive funding, reducing the balance-sheet cushion. This structural erosion increases likelihood of future fundraising, which can be dilutive and limit long-term strategic options if clinical progress stalls.

Isofol Medical AB Business Overview & Revenue Model

Company Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Isofol Medical AB generates revenue primarily through the development and commercialization of its lead product, arfolitixorin. Revenue streams include licensing agreements, collaborations with pharmaceutical companies, and potential sales upon regulatory approval. The company engages in strategic partnerships to facilitate research, development, and distribution, which contribute to its earnings. Additionally, Isofol may receive milestone payments and royalties from partner collaborations, further supporting its financial model. The company's focus on oncology treatments positions it to benefit from the growing demand for cancer therapies globally.

Isofol Medical AB Financial Statement Overview

Summary

Pre-commercial profile with revenue collapsing to 0 in 2024–2025, persistent net losses (worsening to ~-54.2M in 2025), and ongoing operating cash burn (~-51.9M in 2025). Positives include very low leverage (no debt in 2023–2025) and materially reduced cash burn versus 2020–2022, but equity has eroded materially over time, implying continued funding dependence.

Income Statement

The company remains in a pre-commercial profile with very limited revenue (revenue fell from 12.8M in 2022 to 0.7M in 2023 and 0 in 2024–2025), while losses are persistent and sizeable. Net income stayed negative every year and worsened again in 2025 (net loss of ~54.2M vs ~43.5M in 2024), indicating ongoing cost burden without a revenue base to absorb it. A key positive is that operating losses are dramatically smaller than 2020–2022 levels, but profitability is still far from breakeven and recent revenue trajectory is weak.

Balance Sheet

Leverage is very low (total debt at 0 in 2023–2025, and minimal in earlier years), which reduces financial risk. However, equity has been volatile and materially lower than peak levels (equity declined from 318.2M in 2021 to 107.9M in 2025), reflecting accumulated losses and/or funding dynamics. Returns on equity are consistently negative, underscoring that capital is not yet generating profits. Overall: a low-debt balance sheet, but ongoing losses are eroding the equity cushion over time.

Cash Flow

Cash generation remains weak with consistently negative operating cash flow, including ~-51.9M in 2025 and ~-42.0M in 2024. Cash burn improved substantially versus 2020–2022 (when operating cash flow was roughly -160M to -191M), which is a notable strength. That said, the business is still consuming cash each year and free cash flow is negative in most periods (and shown as 0 in 2025), leaving continued dependence on external funding unless revenues ramp meaningfully.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	721.00K	12.80M	22.41M
Gross Profit	0.00	-38.73M	-34.41M	-165.71M	-174.31M
EBITDA	-54.76M	-47.21M	-37.02M	-159.73M	-198.49M
Net Income	-54.17M	-43.49M	-37.07M	-159.79M	-200.25M
Balance Sheet
Total Assets	129.40M	98.42M	140.60M	213.46M	401.36M
Cash, Cash Equivalents and Short-Term Investments	126.99M	96.16M	138.15M	190.58M	379.45M
Total Debt	0.00	0.00	0.00	3.95M	1.65M
Total Liabilities	21.52M	20.47M	19.16M	54.99M	83.13M
Stockholders Equity	107.87M	77.94M	121.43M	158.48M	318.23M
Cash Flow
Free Cash Flow	0.00	-41.99M	-52.54M	-190.97M	-188.43M
Operating Cash Flow	-51.94M	-41.99M	-52.54M	-190.97M	-188.43M
Investing Cash Flow	0.00	0.00	101.00K	0.00	0.00
Financing Cash Flow	84.07M	0.00	0.00	23.00K	450.48M

Isofol Medical AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Positive. The current price of 0.72 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.68, and below the 200-day MA of 0.81, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.72 is Neutral, neither overbought nor oversold. The STOCH value of 41.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ISOFOL.

Isofol Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ISOFOL	49 Neutral	kr193.96M	-2.92	-51.35%	―	―	-34.02%
XINT	49 Neutral	kr218.76M	-4.03	―	―	-7.68%	17.93%
ACTI	45 Neutral	kr126.53M	-1.66	-1291.15%	―	―	28.54%
IRLAB.A	43 Neutral	kr138.28M	-1.72	-199.86%	―	69.03%	23.10%
MODTX	43 Neutral	kr36.73M	-1.03	-166.94%	―	―	-19.35%

Isofol Medical AB Corporate Events

Isofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer

Isofol Medical has reported encouraging interim data from its ongoing phase Ib/II study of arfolitixorin in RAS-mutated metastatic colorectal cancer, an especially hard-to-treat patient group. Conducted initially at Charité – Universitätsmedizin Berlin, the trial is testing an optimized dosing regimen and is now assessing a third dose level of 300 mg/m2, with plans to expand to additional hospitals and a broader phase II cohort including a control arm.

All patients evaluated so far have shown tumor shrinkage without dose-limiting side effects, with reductions in total tumor burden of up to about 50 percent. Notably, half of the six patients assessed have responded so strongly that they were taken off study to be considered for tumor surgery, a rare possibility in this population, underscoring the potential of arfolitixorin to address a major treatment gap in colorectal cancer, the world’s third most common malignancy and a leading cause of cancer death.

Investigators and company management describe the results as unexpectedly positive, highlighting both the apparent safety and the early efficacy signal from the new dosing strategy. Isofol plans to present additional data from the trial at medical conferences later in the year, a development that could influence its clinical strategy and strengthen its positioning in the competitive oncology drug-development landscape.

The most recent analyst rating on (SE:ISOFOL) stock is a Sell with a SEK0.56 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

Isofol strengthens arfolitixorin program with new EU patent and advancing trials

Isofol Medical AB continued development of its lead cancer drug candidate arfolitixorin during the fourth quarter of 2025, advancing a phase Ib/II study in metastatic colorectal cancer with dose escalation up to 300 mg/m² and planning a phase II start later in 2026. The company reported a quarterly loss of kSEK 12,777 and a full-year loss of kSEK 54,168 with no revenue, but ended the year with kSEK 126,990 in cash and proposed no dividend, underlining its development-stage and cash-consuming profile.

Arfolitixorin attracted significant international attention as Isofol presented its study design at major oncology conferences ESMO in Berlin and ASCO-GI in the U.S., while also courting investors and partners at J.P. Morgan Week and Nordic investor events. The European Patent Office’s decision to grant a new product patent for arfolitixorin with protection until 2043 strengthens Isofol’s intellectual property position and supports its strategy to make arfolitixorin a cornerstone of future first-line cancer therapies, including through collaboration with Japanese partner Solasia Pharma K.K.

Management signals 2026 as a pivotal year, with expected data readouts from ongoing studies, further regulatory and partnering activities, and preparation for expansion of arfolitixorin into additional indications beyond metastatic colorectal cancer. This combination of advancing clinical development, reinforced patent protection and active investor and partner engagement could enhance Isofol’s competitive standing in oncology drug development while concentrating execution risk around the coming clinical milestones.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.61 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances

Isofol Medical AB will participate in the ASCO GI Cancer Symposium in San Francisco, where it will present a Trial in Progress abstract outlining the design and recruitment status of its ongoing phase Ib/II study of arfolitixorin in metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, tests a new dosing regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy, oxaliplatin and bevacizumab as first-line treatment, underscoring the candidate’s potential to address a significant treatment gap in one of the world’s most common and deadly cancers. Company executives describe the congress appearance and planned advisory-board meetings as an important start to the year, as Isofol aims to complete the first part of the trial and move into phase II, a step that could prove pivotal for its clinical development program and its positioning in colorectal cancer therapeutics.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.69 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

Isofol Medical to Showcase Arfolitixorin at Upcoming Investor Meetings

Isofol Medical AB announced its participation in several investor meetings in December and January to present its drug candidate, arfolitixorin. This drug is currently in a phase Ib/II clinical study and has the potential to address a significant treatment gap in cancer care. The company’s CEO, Petter Segelman Lindqvist, will present at various events, highlighting the drug’s potential impact on cancer treatment.